Healthcare Industry News: Third Rock Ventures
News Release - September 5, 2018
ArcherDX, Inc. Names Former Foundation Medicine Executive Steven Kafka, Ph.D. to its Board of DirectorsBOULDER, Colo., Sept. 5, 2018 -- (Healthcare Sales & Marketing Network) -- ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine, today announced the appointment of Steven Kafka, Ph.D., to its board of directors.
"We are extremely excited that Steve has joined our board of directors," said Jason Myers, Ph.D., chief executive officer of ArcherDX. "Steve is a highly regarded biotechnology industry leader with a unique combination of skills and experiences that will make an immediate impact on our organization as we continue to rapidly grow our biopharmaceutical research and oncology sequencing businesses."
Dr. Kafka is currently a venture partner with Third Rock Ventures, a leading healthcare venture firm focused on disruptive areas of science and medicine to discover, launch and build companies that make a difference in the lives of patients. Prior to Third Rock Ventures, Steve served initially as chief business officer, then as president and chief operating officer at Foundation Medicine, Inc., a company dedicated to transforming cancer care by identifying the unique drivers of each patient's cancer and matching them with potential targeted therapies and immunotherapies. During his tenure with Foundation Medicine, Dr. Kafka was responsible for growing revenue and scaling operations across both biopharma and clinical businesses, including launching products, expanding the product portfolio to a global scale, driving key business development relationships and financing the company. In addition, Dr. Kafka has held executive roles at oncology drug discovery and development companies including as chief operating officer and chief financial officer for Aileron Therapeutics, and vice president of finance for Infinity Pharmaceuticals. Dr. Kafka earned a B.A. with distinction and honors in economics and political science from Stanford University and a Ph.D. in political economy and government from Harvard University.
"ArcherDX has built a compelling molecular analysis platform with their unique Anchored Multiplex PCR (AMP™) technology and is well positioned to lead the next wave of democratization of personalized medicine in oncology and immunology," said Dr. Kafka. "I look forward to working with Jason and the leadership team to continue to build a great company that can positively impact that lives of cancer patients around the world."
ArcherDX is advancing molecular pathology with a robust technology platform for genetic mutation detection by next-generation sequencing. By combining patented Anchored Multiplexed PCR (AMP™) chemistry in an easy-to-use, lyophilized format and powerful bioinformatics software, the Archer® platform dramatically enhances genetic mutation identification and discovery. ArcherDX provides oncology-focused research products and is pursuing regulatory approval for multiple companion diagnostic assays. Learn more at archerdx.com.
ArcherDX is headquartered in Boulder, Colorado.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring (PCM) Assays for Minimal Residual Disease (MRD)
ArcherDX Receives Breakthrough Device Designation to Detect NTRK Gene Fusions
ArcherDX Receives Approval for Archer(R)MET Companion Diagnostic for TEPMETKO(R) (Tepotinib) in Advanced Non-Small Cell Lung Cancer in Japan